Objective: Fully humanized monoclonal antibodies have revolutionized the treatment of
many solid tumors, including ovarian, lung, colorectal, and breast cancer. Among the most widely used
monoclonal antibodies in clinical oncology are cetuximab, trastuzumab, rituximab, and bevacizumab.
Methods: This is a review article focusing on the drug patents for cetuximab, trastuzumab, rituximab,
Results: These four monoclonal antibodies are used in both first and second line treatment regimens for
multiple common malignancies. With recent patent expirations, pharmaceutical companies involved in
biosimilar manufacture are looking to establish ownership over these financial monopolies.
Conclusion: This article will review these four notable monoclonal antibodies, their role in clinical oncology,
and the drug patents that are nearing expiration. There are currently only two biosimilars approved
in the United States: the trastuzumab biosimilar trastuzumab-dkst (Ogivri) and the bevacizumab
biosimilar bevacizumab-awwb (Mvasi). In Europe, SB3, a trastuzumab biosimilar, is approved for use
as well as two rituzimab biosimilars, truxima and rixathon.